La terapia della sclerosi multipla

  • Simona Bonavita
  • Alessandro d’Ambrosio
  • Gioacchino Tedeschi

Riassunto

Allo stato attuale non esiste alcuna terapia in grado di guarire la sclerosi multipla (SM), ma le terapie a nostra disposizione permettono, a seconda della fase della malattia e del suo decorso, di trattare efficacemente l’episodio acuto, ridurre la frequenza delle ricadute e, parzialmente, la disabilità e di migliorare alcuni sintomi. Globalmente, pertanto, siamo in grado di modificare il decorso della malattia.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Refrences

  1. 1.
    Sellebjerg F, Barnes D, Filippini G et al (2005) EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 12:939–946PubMedCrossRefGoogle Scholar
  2. 2.
    Weinshenker BG, O’Brien PC, Petterson TM et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Neurology 46:878–886Google Scholar
  3. 3.
    The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277–1285Google Scholar
  4. 4.
    PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504CrossRefGoogle Scholar
  5. 5.
    Schwid SR, Goodman AD, Mattson DH (1997) Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon β-1b. Arch Neurol 54:1169–1190PubMedGoogle Scholar
  6. 6.
    Rotondi M, Oliviero A, Profice P et al (1998) Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon β therapy for multiple sclerosis. J Endocrin Invest 21:748–752Google Scholar
  7. 7.
    Durelli L, Ferrero B, Oggero A et al (1999) Autoimmune events during interferon β-1b treat-ment for multiple sclerosis. J Neurol Sci 162:74–83PubMedCrossRefGoogle Scholar
  8. 8.
    Yoshida EM, Rasmussen SL, Steinbrecher UP et al (2001) Fulminant liver failure during interferon β treatment of multiple sclerosis. Neurology 56:1416PubMedGoogle Scholar
  9. 9.
    Li DK, Paty DW (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta 1a Subcutaneously in Multiple Sclerosis. Ann Neurol 46:197–206PubMedCrossRefGoogle Scholar
  10. 10.
    Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898–904PubMedCrossRefGoogle Scholar
  11. 11.
    Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582PubMedCrossRefGoogle Scholar
  12. 12.
    Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249PubMedCrossRefGoogle Scholar
  13. 13.
    Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370:389–397PubMedCrossRefGoogle Scholar
  14. 14.
    Panitch H, Miller A, Paty D et al (2004) Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63:1788–1795Google Scholar
  15. 15.
    Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56:1496–1504Google Scholar
  16. 16.
    Sørensen PS, Deisenhammer F, Duda P et al (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12:817–827PubMedCrossRefGoogle Scholar
  17. 17.
    Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268–1276PubMedGoogle Scholar
  18. 18.
    Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374:1503–1511PubMedCrossRefGoogle Scholar
  19. 19.
    O’Connor P, Filippi M, Arnason B et al (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8:889–897PubMedCrossRefGoogle Scholar
  20. 20.
    Mikol DD, Barkhof F, Chang P et al (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7:903–914PubMedCrossRefGoogle Scholar
  21. 21.
    Johnson KP, Brooks BR, Cohen JA et al (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50:701–708PubMedGoogle Scholar
  22. 22.
    Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910PubMedCrossRefGoogle Scholar
  23. 23.
    Yousry TA, Major EO, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933PubMedCrossRefGoogle Scholar
  24. 24.
    Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431–441PubMedCrossRefGoogle Scholar
  25. 25.
    Neuhaus O, Kieseier BC, Hartung HP (2006) Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 109:198–209PubMedCrossRefGoogle Scholar
  26. 26.
    Millefiorini E, Gasperini C, Pozzilli C et al (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244:153–159PubMedCrossRefGoogle Scholar
  27. 27.
    Casetta I, Iuliano G, Filippini G (2009) Azathioprine for multiple sclerosis. J Neurol Neurosurg Psychiatry 80:131–132PubMedCrossRefGoogle Scholar
  28. 28.
    Gehlsen GM, Grigsby SA, Winant DM (1984) Effects of an aquatic fitness program on the muscular strength and endurance of patients with multiple sclerosis. Phys Ther 64:653–657PubMedGoogle Scholar
  29. 29.
    Gehlsen G, Beekman K, Assmann N et al (1986) Gait characteristics in multiple sclerosis: progressive changes and effects of exercise on parameters. Arch Phys Med Rehab 67:536–539Google Scholar
  30. 30.
    Jonsson A, Korfitzen EM, Heltberg A et al (1993) Effects of neuropsychological treatment in patients with multiple sclerosis. Acta Neurol Scand 88:394–400PubMedCrossRefGoogle Scholar
  31. 31.
    Svensson B, Gerdle B, Elert J (1994) Endurance training in patients with multiple sclerosis; Five case studies. Phys Ther 74:1017–1024PubMedGoogle Scholar
  32. 32.
    Fuller KJ, Dawson K, Wiles CM (1996) Physiotherapy and mobility in multiple sclerosis: a controlled study. Clin Rehab 10:195–204CrossRefGoogle Scholar
  33. 33.
    Petajan JH, Gappmaier E, White AT et al (1996) Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 39:432–441PubMedCrossRefGoogle Scholar
  34. 34.
    Driessen MJ, Dekker J, Lankhorst GJ et al (1997) Occupational therapy for patients with chronic diseases. Disab Rehab 19:198–204CrossRefGoogle Scholar
  35. 35.
    Freeman JA, Langdon DW, Hobart JC et al (1997) The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 42(2):236–244PubMedCrossRefGoogle Scholar
  36. 36.
    Freeman JA, Langdon DW, Hobart JC et al (1999) Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 52:50–56PubMedGoogle Scholar
  37. 37.
    Bowcher H, May M (1998) Occupational therapy for the management of fatigue in multiple sclerosis. Br J Occup Ther 61:488–492Google Scholar
  38. 38.
    Di Fabio RP, Soderberg J, Choi T et al (1998) Extended outpatient rehabilitation: its influence on symptom frequency, fatigue and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehab 79:141–146CrossRefGoogle Scholar
  39. 39.
    Lord SE, Wade DT, Halligan PW (1998) A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomized controlled study. Clin Rehab 2:477–486CrossRefGoogle Scholar
  40. 40.
    Mendozzi L, Pugnetti L, Motta A et al (1998) Computer assisted memory retraining of patients with multiple sclerosis. It J Neurol Sci 19:S431–S432CrossRefGoogle Scholar
  41. 41.
    Plohmann AM, Kappos L, Ammann W et al (1998) Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 455–462Google Scholar
  42. 42.
    Jones R, Davies-Smith A, Harvey L (1999) The effect of weighted leg raises and quadriceps strength, EMG and functional activities in people with multiple sclerosis. Physiotherapy 85:154–161CrossRefGoogle Scholar
  43. 43.
    Solari A, Filippini G, Gasco P et al (1999) Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 52:57–62PubMedGoogle Scholar
  44. 44.
    Mathiowetz V, Matuska KM, Murphy ME (2001) Efficacy of an energy conservation course for persons with multiple sclerosis. Arch Phys Med Rehab 82:449–456CrossRefGoogle Scholar
  45. 45.
    Peterson C (2001) Exercise in 94 degrees F water for a patient with multiple sclerosis. Phys Ther 81:1049–1058PubMedGoogle Scholar
  46. 46.
    Wiles CM, Newcombe RG, Fuller KJ et al (2001) Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 70:174–179PubMedCrossRefGoogle Scholar
  47. 47.
    Mostert S, Kesserling J (2002) Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 8:161–168PubMedCrossRefGoogle Scholar
  48. 48.
    O’Hara L, Cadbury H, De Souza L et al (2002) Evaluation of the effectiveness of professionally guided self-care for people with multiple sclerosis living in the community: a randomized controlled trial. Clin Rehab 16:119–128CrossRefGoogle Scholar
  49. 49.
    Vanage SM, Gilbertson KK, Mathiowetz V (2003) Effects of an energy conservation course on fatigue impact for persons with progressive multiple sclerosis. Am J Occup Ther 57:315–323PubMedCrossRefGoogle Scholar
  50. 50.
    Carter P, White CM (2003) The effect of general exercise training on effort of walking in patients with multiple sclerosis. 14th International World Confederation for Psysical Therapy, BarcelonaGoogle Scholar
  51. 51.
    Chiaravalloti ND, Demaree H, Gaudino EA et al (2003) Can the repetition effect maximize learning in multiple sclerosis? Clin Rehabil 17:58–68PubMedCrossRefGoogle Scholar
  52. 52.
    Craig J, Young CA, Ennis M et al (2003) A randomised controlled trial comparing rehabili-tation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J Neurol Neurosurg Psychiatry 74:1225–1230PubMedCrossRefGoogle Scholar
  53. 53.
    O’Connell R, Murphy RM, Hutchinson M et al (2003) A controlled study to assess the effects of aerobic training on patients with multiple sclerosis. 14th International World Confederation for Psysical Therapy, BarcelonaGoogle Scholar
  54. 54.
    Patti F, Ciancio MR, Cacopardo M et al (2003) Effects of a short outpatients rehabilitation treatment on disability on multiple sclerosis patients: a randomised controlled trial. J Neurol 250:861–866PubMedCrossRefGoogle Scholar
  55. 55.
    DeBolt LS, McCubbin JA (2004) The effect of home-based resistance exercise on balance, power and mobility in adults with multiple sclerosis. Arch Phys Med Rehab 85:290–297CrossRefGoogle Scholar
  56. 56.
    Steultjens EMJ, Dekker J, Bouter LM et al (2003) Occupational therapy for multiple sclerosis. The Cochrane Database of Systematic Reviews, Issue 3Google Scholar
  57. 57.
    Rietberg MB, Brooks D, Uitdehaag BMJ et al (2004) Exercise therapy for multiple sclerosis. The Cochrane Database of Systematic Reviews, Issue 3Google Scholar
  58. 58.
    Rousseaux M, Perennou D (2004) Comfort care in severely disabled multiple sclerosis patients. J Neurol Sci 222:39–48PubMedCrossRefGoogle Scholar
  59. 59.
    Rossiter D, Thompson AJ (1995) Introduction of integrated care pathways for patients with multiple sclerosis in an inpatient neurorehabilitation setting. Disab Rehab 17:443–448CrossRefGoogle Scholar
  60. 60.
    Rossiter DA, Edmondson A, Al-Shahi R et al (1998) Integrated care pathways in multiple sclerosis rehabilitation: completing the audit cycle. Mult Scler 4:85–89PubMedGoogle Scholar
  61. 61.
    Clanet MG, Brassat D (2000) The management of multiple sclerosis. Curr Op Neurol 13:263–270CrossRefGoogle Scholar
  62. 62.
    Freeman JA, Thompson AJ (2001) Building an evidence base for multiple sclerosis management: support for physiotherapy. J Neurol Neurosurg Psychiatry 70:147–148PubMedCrossRefGoogle Scholar
  63. 63.
    Thompson AJ (2001) Symptomatic management and rehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 71(suppl II):II22–II27PubMedGoogle Scholar
  64. 64.
    Thomas PW, Thomas S, Hillier C et al (2006) Psychological interventions for multiple sclerosisl. Cochrane Database Syst Rev 25:CD004431Google Scholar
  65. 65.
    O’Brien AR, Chiaravalloti N, Goverover Y et al (2008) Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil 89:761–769PubMedCrossRefGoogle Scholar
  66. 66.
    Chiaravalloti ND, Deluca J, Moore NB et al (2005) Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Mult Scler 11:58–68PubMedCrossRefGoogle Scholar
  67. 67.
    Solari A, Motta A, Mendozzi L et al (2004) Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. J Neurol Sci 222:99–104PubMedCrossRefGoogle Scholar
  68. 68.
    Tesar N, Bandion K, Baumhackl U (2005) Efficacy of a neuropsychological training programme for patients with multiple sclerosis-a randomised controlled trial. Wen Klin Wochenschr 117:747–754CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2011

Authors and Affiliations

  • Simona Bonavita
    • 1
  • Alessandro d’Ambrosio
    • 2
  • Gioacchino Tedeschi
    • 3
  1. 1.Dipartimento di Scienze NeurologicheSeconda Università di Napoli - SUNNapoli
  2. 2.Dipartimento di Scienze NeurologicheSeconda Università di Napoli - SUNNapoli
  3. 3.Dipartimento di Scienze NeurologicheSeconda Università di Napoli - SUNNapoli

Personalised recommendations